Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Shanghai Pharmaceuticals Holding Co's 5-Year RORE % for the quarter that ended in Mar. 2026 was -1.71%.
SHPMF's 5-Year RORE % is ranked worse than 57.43% of 101
companies
in the Medical Distribution industry
Industry Median: 4.53
vs SHPMF: -1.71
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMF) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Shanghai Pharmaceuticals Holding Co 5-Year RORE % Related Terms
Shanghai Pharmaceuticals Holding Co 5-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co 5-Year RORE % Chart
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co 5-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Shanghai Pharmaceuticals Holding Co (SHPMF) has a 5-Year RORE % of -1.71 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #58 out of 101 companies in the Medical Distribution industry, placing it in the top 57.4%.
Is Shanghai Pharmaceuticals Holding Co's 5-Year RORE % too high?
Shanghai Pharmaceuticals Holding Co's current 5-Year RORE % is -1.71. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #58 out of 101 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's 5-Year RORE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #58 out of 101 companies for 5-Year RORE %. This places Shanghai Pharmaceuticals Holding Co in the lower half of its industry. The industry median 5-Year RORE % is 4.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Distribution company?
The median 5-Year RORE % among Medical Distribution companies is 4.53, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median 5-Year RORE % is 4.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current 5-Year RORE % is -1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current 5-Year RORE % of -1.71. The stock's GF Value™ is $1.81, compared to a current price of $1.46 — trading 19.3% below its estimated fair value. The current 5-Year RORE % is -1.71. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current 5-Year RORE % is -1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $1.46 is trading 19.3% below its estimated GF Value™ of $1.81.
Key valuation signals for SHPMF:
5-Year RORE %: -1.71
GF Value™: $1.81 vs. price of $1.46 (19.3% below fair value)
No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
73GF Score
Get the complete analysis for SHPMF
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMF has been successfully added to your 
